Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry.

ABSTRACT:

Background

Until the approval of dabigatran etexilate, treatment choices for stroke prevention in patients with atrial fibrillation (AF) were vitamin K antagonists (VKAs) or antiplatelet drugs. This analysis explored whether availability of non-vitamin K antagonist oral anticoagulants post-dabigatran approval was associated with changing treatment patterns in China.

Methods

Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) collected data on antithrombotic therapy choices for patients with newly diagnosed nonvalvular AF at risk for stroke. In China, enrollment in phase 1 (before dabigatran approval) and phase 2 (after dabigatran approval) occurred from 2011 to 2013 and 2013 to 2014, respectively. Analyses were restrict

SUBMITTER: Ma C 

PROVIDER: S-EPMC7279964 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature